CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
原文出处:CNBC (本文由聚合程序自动采集,版权归原作者所有)